Clinical Trials · NCT06897475
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 240
- Start date
- Mar 2025
- Locations
- 60 sites, 6 countries
- Primary endpoint
- Change from Baseline in Hemoglobin A1c (HbA1c)